Craigavon, N.I. – Almac Sciences, a member of the Almac Group, has expanded its technology capabilities within its Active Pharmaceutical Ingredients (API) services & chemical development portfolio with the implementation of continuous flow expertise at its global headquarters in Craigavon, UK, with further plans to introduce flow capacity within Arran Chemical Company (Athlone, Ireland).
Continuous flow manufacture is an innovative technology platform which is gaining momentum within the pharmaceutical industry with the FDA supporting the adoption for the manufacture of APIs. It offers significant improvements in relation to product quality, process safety, reduction in plant footprint and provides the ability to perform chemistry that is difficult or impossible to do in batch mode.
Almac Sciences has a 4-year strategy to develop Flow Assisted Synthesis Technology (FAST) focusing on four key areas; (1) high pressure hydrogenations, (2) high energy chemistry, (3) oxidation and (4) photo-redox LED mediated chemistries. To support this, Almac Sciences has been awarded a Knowledge Transfer Partnership from Innovate UK for the development of novel routes to chiral amines using flow technology. In addition, Arran Chemical Company, in partnership with Queen’s University, Belfast, has been successful in securing a Horizon 2020 funded programme to support 4 PhD studentships for the next 4 years (beginning in 2019) in line with the FAST strategy.
Almac will develop highly flexible, robust, efficient flow technology platforms for continuous manufacture for the benefit of its clients who seek high quality and best-in-class pharmaceutical synthesis.
Prof. Tom Moody, VP Technology Development & Commercialisation, Almac & Arran Chemical Company commented, “The introduction of continuous flow technology further enhances Almac Sciences’ capabilities within API development and manufacture. Flow technology is highly flexible, robust, economic and regarded as the most exciting and innovative growth technology for the preparation of APIs. We are delighted to now offer this within our portfolio and will strive to continue providing world-class solutions to advance human health globally.”
DSM significantly reduces CO2 emissions at vitamin production facility in Sisseln, Switzerland
DSM announced that it reduces CO2 emissions at its vitamin production facility in Sisseln, Switzerland, by 50,000 tons/year.
Nouryon starts work on chloromethanes expansion in Germany
Nouryon will start construction in May on a project to further increase capacity for chloromethanes at its site in Frankfurt, Germany. The expansion is expected to be completed in 2020.
Ercros expands its moulding compounds production capacity
The Ercros factory in Cerdanyola has expanded the production capacity of moulding compounds by 3,000 t/year, which represents an increase of 14% to reach 25,000 t/year.
Merck Invests in Expansion of Manufacturing Capacity for Biotech Medicines
€150 million investment over the 2019-2023 period in manufacturing site at Aubonne, Switzerland. Expansion supports growth of current and future portfolio of Merck’s biotech medicines for patients ...